Seer to Present at the 39th Annual J.P. Morgan Healthcare Conference
Seer, Inc. (Nasdaq: SEER), a life sciences company, will participate in the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer, Inc. (Nasdaq: SEER), a life sciences company, will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:40 a.m. PT. The event will feature a presentation and Q&A session with company management. A live webcast will be accessible through the Investor section of Seer's website, with an archived replay available post-conference.
Seer focuses on delivering unbiased, rapid, and scalable proteomics information, primarily through its Proteograph™, enhancing scientific research efficiency.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was +7.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference.
Seer’s management is scheduled to present and participate in a Q&A session on Monday, January 11 at 8:40 a.m. Pacific Time / 11:40 a.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.
About Seer
Seer is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. Seer is developing its Proteograph™, which is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. Seer designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers.
Investor Contact
Carrie Mendivil
investor@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.